Quantitation of antidepressants by mass spectrometry

Mass spectrometry methods enable accurate detection and quantification of antidepressants and metabolites, addressing compliance and polypharmacy challenges by precisely measuring drug levels in patients, thereby preventing harmful interactions.

JP7742207B2Active Publication Date: 2025-09-19QUEST DIAGNOSTICS INVESTMENTS INC
3 Cites 0 Cited by

Patent Information

Application Number
JP2021570775
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-05-31
Filing Date
2020-05-29
Publication Date
2025-09-19
Estimated Expiration
2040-05-29

AI Technical Summary

Technical Problem

Existing methods for accurately detecting and quantifying antidepressants and their metabolites in patients are inadequate, particularly for monitoring compliance and avoiding adverse drug interactions, as some antidepressants can have harmful side effects when mixed with other drugs.

Method used

A method using mass spectrometry for detecting and quantifying antidepressants and metabolites by ionization, fragmentation, and determining ion amounts to assess their presence or amount in a sample, including tandem mass spectrometry and internal standards, with techniques like liquid chromatography and various ionization modes.

Benefits of technology

The method enables precise detection and quantification of multiple antidepressants and metabolites in the range of 4 ng/mL to 5000 ng/mL, facilitating effective compliance monitoring and preventing polypharmacy issues.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Methods for detecting or determining the amount of an antidepressant and / or antidepressant metabolite in a sample are described. More particularly, mass spectrometry methods for detecting and quantifying an antidepressant and / or antidepressant metabolite in a sample are described.
Need to check novelty before this filing date? Find Prior Art